NRM on Vascular Perfusion in Healthy Adults

What Was Tested

This registered not phased trial tested NAD+.

The purpose of this study is to better understand the effects of nicotinamide riboside supplement in overall cardiovascular health in healthy adults.

It had three arms (groups): one (active comparator), one (active comparator) and Placebo (placebo comparator).

2 identical Placebo capsules twice a day for 12 weeks.

The registry classes the interventions as dietary supplement and other.

More on the Plan

Participants will be randomly assigned to one of three groups.

Study measurements will be completed at three timepoints and intervention taken daily throughout the subject's 12 weeks of participation.

Who Took Part

The registry lists 200 planned participants were the target.

It was open to people of any sex aged from 35 years up to 70 years.

Healthy volunteers could join, not only people with the condition.

Examples of who could join: \>= 35 and \<=70. Provides consent to participate in the study. Not pregnant at time of consent. Understands and agrees to follow all study procedures and limitations.

The full record lists 5 inclusion and 10 exclusion criteria; among the exclusions: pregnant, nursing, or trying to conceive; BMI Restrictions: \<35; allergy or sensitivity to study agent ingredients.

How the Study Was Run

The set-up was randomized, parallel-group and triple-blind.

Random assignment meant chance, not the researchers, decided who got NAD+ and who got the comparison, which limits bias.

The NAD+ group and the comparison group ran side by side rather than switching.

Neither the participants nor the staff measuring them knew who was on NAD+, so expectations could not easily colour the readings.

Those kept unaware of assignments: participant, care provider and investigator.

It started in 2024-11-25 with completion listed for 2026-09-30.

It ran at 1 site in United States.

Its stated primary purpose is prevention.

What This Means in Plain Language

Put simply, this is a not phased, randomized trial of NAD+ in 200 people.

Its status is enrolling by invitation; no results are posted to the registry yet, so nothing here describes outcomes.

More context: the NAD+ compound page, all human trials.